Acasti Pharma Inc. (NASDAQ:ACST) an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces that on November 7, 2014 it received notification from the NASDAQ Listing Qualifications Department for failing to maintain a minimum bid price of US$1.00 per share for the last 30 consecutive business days, as required by NASDAQ Listing Rule 5550(a)(2) — bid price. Acasti Pharma Inc. (NASDAQ:ACST) in last trading activity decreased -10.85% to close at $0.41. Company weekly performance is -16.31% while its quarterly performance stands at -57.28%. Acasti Pharma Inc. (NASDAQ:ACST) is -99.40% away from its 52 week high.

For the three months ended September 30, 2014, Recro Pharma Inc. (NASDAQ:REPH) on 10 November reported a net loss applicable to common shareholders of $4.7 million, or $0.61 per share, compared to a net loss applicable to common shareholders of $0.6 million, or $3.95 per share, for the comparable period in 2013. The third quarter of 2013 includes accretion of Recro Pharma’s redeemable convertible preferred stock. On last trading day Recro Pharma, Inc. (NASDAQ:REPH) decreased -1.47% to close at $2.69. Its volatility for the week is 5.46% while volatility for the month is 4.65%. Recro Pharma, Inc. (NASDAQ:REPH) monthly performance is -10.93%.

Compugen Ltd. (NASDAQ:CGEN) announced that Dr. Anat Cohen-Dayag President and Chief Executive Officer of Compugen will present a corporate overview and update at the Jefferies 2014 Global Healthcare Conference in London UK. The Compugen presentation is scheduled to start at 10:40 a.m. GMT on Thursday November 20 2014. On last trading day Compugen Ltd. (NASDAQ:CGEN) moved up 0.62% to close at $6.48. Its volatility for the week is 4.51% while volatility for the month is 4.40%. CGEN’s sales growth for past 5 years was 63.50% and its EPS growth for past 5 years was 3.90%. Compugen Ltd. (NASDAQ:CGEN) monthly performance is -15.84%.

For the three-month period ending Sept. 30, ContraFect Corporation (NASDAQ:CFRX) reported total unaudited assets of just more than $34 million, up from less than $10 million at the end of 2013. The company operated at a net loss for the third quarter of $16,397,678, a net loss per diluted share of common stock of $1.22. ContraFect has a net loss of $25,412,413 for the calendar year, which does not include a roughly $4.5 million dividend to its preferred stockholders. Overall, the company has a net loss per share of common stock of $5.76 for 2014. ContraFect Corporation (NASDAQ:CFRX) has 5.70% insider ownership while its institutional ownership stands at 0.90%. In last trading activity company’s stock closed at $2.80.

OXiGENE Inc., (NASDAQ:OXGN) a biopharmaceutical company developing novel cancer therapeutics, announced in a press release that the company has been granted a patent by the European Patent Office related to its current clinical product candidate, OXi4503. The patent (EP 2219451 B1) is drawn to the use of OXi4503 in treating non-solid myeloid neoplasm, including acute myeloid leukemia (AML). On Tuesday shares of OXiGENE, Inc. (NASDAQ:OXGN) closed at $1.78.